Avoro Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avoro Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-400,000	Closed	-$97.2M	–	38
2024 Q2	$97.2M	Buy	400,000 +100,000	+33%	+$15.8M	1.29%	19
2024 Q1	$44.8M	Sell	300,000 -811,111	-73%	-$135M	0.52%	33
2023 Q4	$213M	Buy	1,111,111 +100,000	+10%	+$17M	2.94%	15
2023 Q3	$179M	Sell	1,011,111 -93,889	-8%	-$17.9M	2.79%	13
2023 Q2	$210M	Hold	1,105,000	–	–	2.85%	13
2023 Q1	$221M	Hold	1,105,000	–	–	3.28%	11
2022 Q4	$263M	Hold	1,105,000	–	–	3.92%	10
2022 Q3	$221M	Sell	1,105,000 -255,000	-19%	-$48.6M	4.09%	11
2022 Q2	$198M	Buy	1,360,000 +60,000	+5%	+$8.51M	3.92%	11
2022 Q1	$212M	Buy	1,300,000 +225,000	+21%	+$34.3M	3.88%	10
2021 Q4	$182M	Buy	1,075,000 +225,000	+26%	+$41.8M	3.1%	10
2021 Q3	$160M	Sell	850,000 -150,000	-15%	-$28.1M	2.52%	12
2021 Q2	$170M	Buy	+1,000,000	New	+$146M	2.95%	10
2018 Q3	–	Sell	-700,100	Closed	-$69M	–	46
2018 Q2	$69M	Buy	+700,100	New	+$69.4M	2.65%	13

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avoro Capital Advisors's ALNY Position: Q3 2024 in Review

Avoro Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 400,000 shares — an estimated $97.2M sold.

Avoro Capital Advisors first reported a position in ALNY in Q2 2018 and held it in 14 quarters. The position peaked at $263M in Q4 2022. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

Avoro Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Avoro Capital Advisors sold 400,000 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $97.2M.
Avoro Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 14 quarters.
Avoro Capital Advisors's Alnylam Pharmaceuticals position peaked at $263M in Q4 2022.
567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Avoro Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.